Bharat Parenterals Ltd reports Desai Shares' open‑market purchase of 1,356 shares

What Bharat Parenterals Ltd announced

Bharat Parenterals Ltd (BSE: 541096) filed a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on 29 June 2026. The filing confirms that Desai Shares and Stock Pvt Ltd – a member of the promoter group – purchased 1,356 equity shares of the company in the open market. The acquisition increased Desai’s shareholding from 27,32,436 shares (39.65 % of diluted capital) to 27,33,792 shares (39.67 % of diluted capital).

Details of the acquisition

• Acquirer: Desai Shares and Stock Pvt Ltd (DIN 06425782), identified as belonging to the promoter group of Bharat Parenterals Ltd.
• Mode of acquisition: Open‑market purchase.
• Acquisition window: Between 1 June 2026 and 5 June 2026, with the transaction completing on 25 June 2026.
• Number of shares acquired: 1,356 equity shares, each carrying voting rights.
• Percentage of total diluted share capital acquired: 0.0197 % (1,356 / 68,91,963).
• Pre‑acquisition holding: 27,32,436 shares (39.65 % of diluted capital).
• Post‑acquisition holding: 27,33,792 shares (39.67 % of diluted capital).

The filing makes clear that no other instruments – such as warrants, convertible securities, or pledged shares – were involved in the transaction. The total share capital of Bharat Parenterals Ltd remains unchanged at 68,91,963 equity shares of Rs 10 each, representing a nominal capital of Rs 6.89 billion both before and after the purchase.

Shareholding structure before and after the purchase

The marginal increase of 1,356 shares does not alter the company’s authorized or issued capital, but it does slightly raise the promoter‑group’s voting power.

Transaction mechanics

The acquisition was executed off‑exchange, meaning the shares were bought directly from existing shareholders rather than through a fresh issue. Because the purchase was made on the open market, there is no immediate dilution of earnings per share for existing investors. The filing notes that the shares were acquired at market prices prevailing between the stated dates, but the exact price per share was not disclosed in the regulatory submission.

The filing also confirms compliance with SEBI’s Substantial Acquisition of Shares & Takeovers (SAST) regulations. Under Regulation 29(2), any acquisition that results in a change of shareholding of 5 % or more must be disclosed. Although the incremental stake is well below that threshold, the acquirer already holds a promoter‑group stake of over 39 %, making the disclosure mandatory under the rule that requires reporting of any change in holdings for entities already classified as promoters.

Key facts at a glance

Why this matters for investors

The disclosure signals that the promoter group is maintaining, and slightly increasing, its control over Bharat Parenterals Ltd. For shareholders, the transaction does not create dilution because no new shares were issued. However, the marginal rise in voting power could influence future board decisions, especially if the promoter group seeks to steer strategic initiatives such as capital raising, acquisitions, or restructuring.

Regulatory compliance is also noteworthy. By filing under SEBI’s SAST rules, the company demonstrates adherence to transparency requirements, which can be reassuring for institutional investors who monitor governance standards. The open‑market nature of the purchase suggests that the acquirer found sufficient liquidity to buy the shares without resorting to a preferential allotment, which might have been perceived as a more aggressive move.

Conclusion

Bharat Parenterals Ltd’s filing on 29 June 2026 confirms that Desai Shares and Stock Pvt Ltd, a promoter‑group entity, bought 1,356 equity shares in the open market, raising its stake to 39.67 % of the diluted share capital. The transaction does not affect the company’s capital structure and complies with SEBI’s Substantial Acquisition regulations. Investors should note the slight increase in promoter control but can expect no immediate dilution or capital‑raising impact from this specific purchase.